LJM716 potently inhibits ErbB3/ Akt phosphorylation and proliferation in both ligand dependent and HER2 amplified ligand-independent ErbB3 dependent cell lines in vitro; it induces tumor growth inhibition or even regression, both as single agent or in combination with other ErbB receptor family targeted agents. This evidence concerns the gene AKT1 and neoplasm.